BridgeBio Pharma Inc. (BBIO)
NASDAQ
Closed
Oct 7, 2026
Day's Range
66.1552 wk Range
52.75Overview - BBIO - BridgeBio Pharma Inc.
Key Statistics
Valuation
Enterprise Value
15.52B
P/E (Trailing)
‪-17.80‬
P/E (Forward)
‪2,395.34‬
PEG Ratio
‪0.99‬
Price / Sales (TTM)
‪18.03‬
Price / Book
‪-5.25‬
EV / EBITDA
‪-32.84‬
Profitability
Gross Margin
‪93.82%‬
Profit Margin
‪-97.02%‬
Operating Margin
‪-43.94%‬
Return on Assets
‪-25.99%‬
Return on Equity
‪34.90%‬
Ownership
Shares Outstanding
195.28M
Float
167.19M
Short % of Shares Outstanding
‪12.31%‬
Held by Insiders
‪3.91%‬
Held by Institutions
‪99.51%‬
Price stats
Beta
‪0.97‬
50-Day Avg
‪77.28‬
200-Day Avg
‪73.70‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
22 analysts
Average price target
‪$ 108.43‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BBIO - BridgeBio Pharma Inc.
Peers - BBIO - BridgeBio Pharma Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
- AXSMNASDAQAxsome Therapeutics Inc.9.37BMarket Cap+33.09%52-week change-48.69P/E (Trailing)‪-24.67%‬Profit Margin
Profile Summary - BBIO - BridgeBio Pharma Inc.
About
BridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
